A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

Novo Nordisk (CSE:NOVOb) (NYSE:NVO) shares slumped Wednesday after Roche (SIX:ROG) struck a $5.3 billion deal to acquire rights to an obesity treatment from Denmark’s Zealand Pharma A/S (CSE:ZELA).

"Billionaire" and "successful hedge fund manager" are titles that carry significant weight on Wall Street. These and others ...

Eli Lilly’s big-selling insulin, Humalog, faces cut-price competition after the US regulator approved a biosimilar from Sanofi. Sanofi’s Admelog (insulin lispro) is approved in type 1 and type ...

Current health news highlights include Nigeria's Lassa fever fight after nearly 100 deaths, WHO's response to U.S. funding ...

Another significant reason that Lilly is able to take such action is that the products which will have their price cut, such as Humalog (insulin lispro), are already seeing their sales fall ...

Novo Nordisk's U.S.-listed shares fell Monday morning following the release of data for a new phase 3 clinical trial of its ...

What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...

On Thursday, Jim Cramer, the host of Mad Money, discussed the recent turbulence in the stock market, pointing to the lack of ...

Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed SGLT2 inhibitor for type-2 diabetes ...

This story mentions weight, weight loss, and/or GLP-1 drugs. In the last few years, GLP-1s, prescription weight-loss ...